

Patient Information	Spec	imen Information	Client Information
	Spec	imen:	
	Requ	isition:	
DOB: AGE:	Lab I	Ref #:	
Gender:	Colle	ected:	
Phone:	Rece		
Patient ID:			
	Repo	oned:	
COMMENTS: FASTI	NG:YES		
Test Name PROTHROMBIN W/INR	+ PARTIAL THROMBOPI	n Range Out Of Range LASTIN TIMES	Reference Range La
PARTIAL THROMBOP			
TIME, ACTIVATE	D 25	7	22-34 sec
This test ha	s not been validate	d for monitoring	
	ed heparin therapy.		
		herapy, please refer	
to the Hepar	in Anti-Xa assay (t	est code 30292).	
For addition	al information, ple	ase refer to	
http://educa	tion.QuestDiagnosti	cs.com/faq/FAQ159	
	s being provided for		
informationa. PROTHROMBIN TIME	l/educational purpo	ses only.)	
INR		. 0	
Reference Rai		0.9-1.1	
	ensity Warfarin The		
Higher-inten:	sity Warfarin Thera	py 3.0-4.0	
PT	10	0.5	9.0-11.5 sec
HS CRP		3.6 Н	mg/L
Higher relat	ive cardiovascular	risk according to AHA/CDC	
guidelines. (Consider retesting	in 1 to 2 weeks to exclud	
		the baseline CRP value	
secondary to	infection or infla	mmation.	
For ages >17			
	Risk According to .		
<1.0 1.0-3.0	Lower relative care	alovascular risk. ardiovascular risk.	
3.1-10.0	Higher relative ca		
	Consider retesting	in 1 to 2 weeks to	
	exclude a benign t		
	in the baseline CR to infection or in		
>10.0		on, upon retesting,	
	may be associated		
	inflammation.		
COMPREHENSIVE META	BOLIC		
PANEL			
GLUCOSE	82	2	65-99 mg/dL
		Fas	sting reference interval
		1	7 DE mar/di
UREA NITROGEN (B			7-25 mg/dL
CREATININE	0	l .81 the reference limit	7-25 mg/dL 0.50-1.05 mg/dL

SPECIMEN:



Patient Information	Specimen Informati	ion	Client Information	
	Specimen:			
	Collected:			
	Received:			
DOB: AGE:				
Gender:	Reported:			
Patient ID:				
Test Name	In Range	Out Of Range	Reference Range	Lab
eGFR NON-AFR. AMERICAN	85		• OR = 60 mL/min/1.73m2	
eGFR AFRICAN AMERICAN	98		OR = 60 mL/min/1.73m2	
BUN/CREATININE RATIO	NOT APPLICAE		5-22 (calc)	
SODIUM	139 4.2		.35-146 mmol/L 8.5-5.3 mmol/L	
POTASSIUM CHLORIDE	4.2		0.5-5.3 mmol/L 08-110 mmol/L	
CARBON DIOXIDE	24		20-32 mmOl/L	
CALCIUM	9.6		3.6-10.4 mg/dL	
PROTEIN, TOTAL	7.3		5.1-8.1 g/dL	
ALBUMIN	4.7		8.6-5.1 g/dL	
GLOBULIN	2.6			
ALBUMIN/GLOBULIN RATIO	1.8		0-2.5 (calc)	
BILIRUBIN, TOTAL	0.5		0.2-1.2 mg/dL	
ALKALINE PHOSPHATASE	50		33-130 U/L	
AST	18		.0-35 U/L	
ALT	19	6	5-29 U/L	
SED RATE BY MODIFIED	C			
WESTERGREN	6		CR = 20 mm/h	
CBC (INCLUDES DIFF/PLT) WHITE BLOOD CELL COUNT	8.3		.8-10.8 Thousand/uL	
RED BLOOD CELL COUNT	5.03		8.80-5.10 Million/uL	
HEMOGLOBIN	14.7		1.7-15.5 g/dL	
HEMATOCRIT	43.9		35.0-45.0 %	
MCV	87.3		80.0-100.0 fL	
MCH	29.2	2	27.0-33.0 pg	
MCHC	33.5		2.0-36.0 g/dL	
RDW	11.8		1.0-15.0 %	
PLATELET COUNT	227		40-400 Thousand/uL	
MPV	11.4		'.5-12.5 fL	
ABSOLUTE NEUTROPHILS	5445 2100		.500-7800 cells/uL 550-3900 cells/uL	
ABSOLUTE LYMPHOCYTES ABSOLUTE MONOCYTES	315		200-950 cells/uL	
ABSOLUTE EOSINOPHILS	349		.5-500 cells/uL	
ABSOLUTE BASOPHILS	91		-200 cells/uL	
NEUTROPHILS	65.6	Q		
LYMPHOCYTES	25.3	0		
MONOCYTES	3.8	90		
EOSINOPHILS	4.2	90		
BASOPHILS	1.1	90	;	
URINALYSIS, COMPLETE				
COLOR	YELLOW		TELLOW	
APPEARANCE	CLEAR		LEAR	
SPECIFIC GRAVITY PH	1.007 6.5		001-1.035 5.0-8.0	
GLUCOSE	NEGATIVE		IEGATIVE	
BILIRUBIN	NEGATIVE		IEGATIVE	
KETONES	NEGATIVE		IEGATIVE	
OCCULT BLOOD	NEGATIVE		IEGATIVE	
PROTEIN	NEGATIVE		IEGATIVE	
NITRITE	NEGATIVE	N	IEGATIVE	
LEUKOCYTE ESTERASE			IEGATIVE	
WBC	• •		OR = 5 / HPF	
RBC	0-2		OR = 2 / HPF	
SQUAMOUS EPITHELIAL CELLS	0-5		OR = 5 / HPF	
BACTERIA		FEW N	IONE SEEN /HPF	

SPECIMEN:



Patient Information		Specimen Informa	Specimen Information			Client Information		
DOB: Gender: Patient ID:	AGE:	Specimen: Collected: Received: Reported:						
Test Name HYALINE CA RHEUMATOID F		In Range NONE SEEN <14	Out Of Range	NONE	rence Range SEEN /LPF IU/mL		Lab	



Patient Information	Specimen Information	Client Information
DOB: AGE: Gender: Patient ID:	Specimen: Collected: Received: Reported:	

Immunology

Test Name	Result	ult Reference Range		Lab
ANA SCREEN, IFA, W/REFL TITER AND PATTERN				
ANA SCREEN, IFA	NEGATIVE	NEGATIVE		

ANA IFA is a first line screen for detecting the presence of up to approximately 150 autoantibodies in various autoimmune diseases. A negative ANA IFA result suggests ANA-associated autoimmune diseases are not present at this time.

Visit Physician FAQs for interpretation of all antibodies in the Cascade, prevalence, and association with diseases at http:// education.QuestDiagnostics.com/ faq/FAQ177

Physician Comments:

PERFORMING SITE:

Quest, Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics.